by University of Pittsburgh
Certain chemotherapy-resistant ovarian cancer cells protect neighboring cancer cells by sending signals that induce resistance, according to a new study from University of Pittsburgh and UPMC researchers that may help explain why ovarian cancer patients respond … Read more
by Alison Kanski
NEW YORK – Personalized phone discussions about genetic risk assessment increased the number of breast and ovarian cancer patients who got genetic testing or discussed their risk with a genetic counselor, a study from Rutgers Cancer Institute … Read more
by Justin Jackson
An international team led by researchers from MacCallum Cancer Center in Melbourne, Australia, examined 391 tumor tissues from about 270 multisite autopsy samples collected from 15 individuals with end-stage high-grade serous ovarian cancer (HGSC). All of the … Read more
Ovarian cancer outcomes are less positive for Black and African American persons compared to other communities, but the reasons why are not entirely clear. Anne Mette Buhl, PhD, Director of Science and Clinical Trials, from The Clearity Foundation, recently contributed … Read more
by Jo Cavallo
The UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) has shown that general population screening did not significantly reduce ovarian and tubal cancer deaths, and the researchers concluded that such screening cannot be recommended. The findings from … Read more
by Jennifer Byrne
Patient withdrawal from cancer clinical trials can result in systematic bias, insufficiently powered studies and a loss of valuable scientific knowledge, according to a study in JAMA Network Open.
Although increased attention has been paid to … Read more
by Jordyn Sava
With encouraging response rates and a well-tolerated safety profile seen in RAMP-201, experts are hopeful for the accelerated approval of avutometinib plus defactinib for low-grade serous ovarian cancer.
The combination of avutometinib (VS-6766) with defactinib (VS-6063), as … Read more
A specific colonization of microbes in the reproductive tract is commonly found in women with ovarian cancer, according to a new study from Mayo Clinic’s Center for Individualized Medicine. The discovery, published in Scientific Reports, strengthens evidence that the … Read more
by Jennifer Southall
Women who underwent surgery for gynecologic cancers experienced decreased symptoms of anxiety and pain with the use of acupressure before surgery and acupuncture during surgery, according to study results published in Cancer.
Further investigation is needed … Read more
by Caroline Seymour
Treatment with the folate receptor α–directed antibody-drug conjugate luveltamab tazevibulin led to a 37.5% overall response rate in Frα-selected patients with advanced ovarian cancer, defined by a tumor proportion score above 25%.
Treatment with the folate receptor
by Anita T. Shaffer
Efforts to target the folate metabolism network have entered a new stage, with the approval of a novel therapy directed at folate receptor–α and the potential for additional agents aimed at that target in solid tumors.… Read more
by Ryan Scott
A triplet regimen comprised of COM701, BMS-986207, and nivolumab was found to have encouraging antitumor activity and favorable tolerability in patients with heavily pretreated, platinum-resistant ovarian cancer.
A triplet regimen comprised of COM701, BMS-986207, and nivolumab (Opdivo)
A genetic test developed in a study at the University of Helsinki and Helsinki University Hospital identifies ovarian cancer patients who benefit from PARP inhibitors, a treatment option.
Since the therapy is associated with potential serious side-effects, it is important … Read more
by Eliza Folsom
Results from a recent Yale Cancer Center Phase II trial studying ixabepilone and bevacizumab vs ixabepilone alone in platinum resistant ovarian cancer patients have led to the combination added as a Category 2B recommended regimen in Ovarian … Read more
— Risk especially high within the first year after cancer diagnosis
by Kristen Monaco
Clearity offers psychosocial support through our Steps Through OC program for patients, survivors and caregivers. If you would like personal one-to-one assistance with the stress and … Read more
by Kalie VanDewater
Reporting of race and ethnicity data and representation of different racial and ethnic populations in OB/GYN clinical trials are subpar, although improvement is possible, according to findings published in JAMA Surgery.
“Although trial results inform policies … Read more
by Jennifer Byrne
A new clinical practice guideline jointly published by ASCO and Society for Integrative Oncology addresses the potential role of integrative pain management techniques in management of cancer-related pain in adults.
“Patients with cancer, as well as cancer … Read more
by Nicolas Wrigley
Findings from a recent 30-year analysis of more than 1,000 gynecologic cancer trials strongly suggest that reporting race and ethnicity must be a required part of clinical research to improve diversity, according to a group of researchers.… Read more
by Teaganne Finn
Actor Patrick Dempsey, 56, has a warm message for all the cancer caregivers— take care of yourself, too. The Greys Anatomy star knows first hand how taxing it can be as a caregiver for a sick loved … Read more
